Answers are grounded in this paper and cite their sources.
Bronchiectasis is a condition characterised by cough, purulent sputum and recurrent chest infections.1 The last 15 years have seen a huge growth in clinical and laboratory research in this condition, culminating in the first-ever licensed drug for bronchiectasis in 2025, the dipeptidyl-peptidase-1 (DPP-1) inhibitor, brensocatib.2 Before antibiotics and vaccination, patients usually succumbed before the age of 40. Over the last 20 years the prevalence has been increasing, particularly in the elderly, and the mean age of patients is 67.3 In the UK the prevalence in females is 0.6% and males 0.5%.4 The diagnosis requires both typical symptoms and evidence of dilatation of ≥ 1 airway on a high-resolution CT scan (Figure 1).5 Top left panel-columnar bronchiectasis with failure to taper; Bottom left panel – varicose bronchiectasis with numerous signet rings (internal diameter of airway > than diameter of accompanying vessel; bottom right panel cystic bronchiectasis with fluid levels; top right panel – ABPA with severe proximal bronchiectasis in right upper and lower lobe which are severely plugged and left upper lobe. Bronchiectasis has multiple aetiologies. The initiating event may be infection, mucociliary dysfunction, chronic inflammation or airway injury. However, progression of disease involves the dynamic interaction of all these processes, termed the “vicious vortex”.6 Neutrophilic inflammation predominates in bronchiectasis with bacteria as the commonest infecting agents. Neutrophils possess mature azurophilic granules containing serine proteases (SP) which are highly bactericidal proteolytic enzymes that can degrade the extracellular matrix (ECM) thus facilitating neutrophil mobility. SP include neutrophil elastase (NE), cathepsin G and proteinase 3.7 NE, the most potent, can reduce the secretion of SP inhibitor serum leukocyte protease inhibitor (SLPI). SP are activated in the bone marrow by the enzyme DPP-1. Other contents include azurocidin, which activates T cells, myeloperoxidase which catalyses reactive oxygen species and hypochlorous acid and defensins. Less mature granules contain lactoferrin which sequesters iron vital for bacterial replication, the anti-microbial protein LL-37, lysozyme which cleaves bacterial cell wall peptidoglycan and matrix metalloproteinase (MMP)-9 which activates defensins and degrades the ECM. Neutrophils also kill microbes extracellularly by degranulation and by forming neutrophil extracellular traps (NETs), web-like structures composed of chromatin which ensnare and kill microbes. Neutrophils secrete chemokines (CXC-1,8, 9) which attract other neutrophils, monocytes and B and T-lymphocytes and pro- inflammatory cytokines (IL-1α,β, 6, 8). Local tissue factors also greatly enhance neutrophilic survival. In bronchiectasis there is evidence of dysregulated persistent neutrophilic inflammation with raised NE levels significantly associated with exacerbations, reduced FEV1, CT Reiff score and other markers of severity. Failure of neutrophil apoptosis may contribute to this and a protease/anti-protease imbalance with low levels of SLPI and TIMP-1, an MMP-9 inhibitor. MMP-9 also deactivates alpha- 1-antitrypsin. Persistently high concentrations of SP, MPO and MMP-9 causes progressive degradation of elastin and collagen such that the integrity of the airway is lost and, eventually, starts to dilate. About 25% of patients have symptoms of bronchiectasis for more than 10 years before diagnosis.8 A common misdiagnosis is chronic bronchitis which is a symptom complex often present in bronchiectasis, asthma, COPD and active smoking. Any patient who produces sputum most days for more than 3 months or experiences ≥ 2 episodes of bronchitis a year may have bronchiectasis. Chest pain, fatigue, dyspnoea, sinus symptoms, anxiety and depression are all common. Haemoptysis is usually small volume indicative of acute infection and airway angiogenesis. Large volume arterial bleeding can occasionally occur and may be life threatening. 35% have airflow obstruction on spirometry.3 Patients undergo a detailed clinical work-up although the cause may be obvious. This is to ensure there is no dual pathology and confirm idiopathic status. It is now recognized that asthma and COPD are causal in 15% of cases.3 In developed countries, idiopathic disease remains the most common cause at up to 38.1%.3 This is highly unsatisfactory as these patients are much less likely to receive precision medicine. This is due to post-pneumonic bronchial injury in nearly two-thirds. In developing countries, post-infective disease predominates with TB a common cause. NTM can also cause bronchiectasis in the lingula and middle lobe with primary nodular dominant disease or fibro-cavitation dominant in COPD and cystic fibrosis. Inhaled corticosteroids (ICS) In asthma bronchiectasis overlap are associated with reduced hospitalization and mortality9 and those with allergy or eosinophilic inflammation, needing > 2 courses of oral steroids/year, should be offered anti-IgE, anti-IL-5 or anti-IL-4 biological therapies which can be steroid sparing.10 ICS prescribing in COPD bronchiectasis overlap should follow the GOLD guidelines as they increase pneumonia risk. Macrolides should be prescribed if the patient has ≥ 2 exacerbations per year. In eosinophilic CBO, unresponsive to ICS, anti-eosinophilic treatments such as mepolizumab, benralizumab (anti- IL-5) or dupilumab (anti-IL-4/IL-13) may be helpful.11 Allergic Bronchopulmonary Aspergillosis (ABPA) counts for 3% of bronchiectasis, a likely under-estimation due to undertesting. It causes proximal bronchiectasis in asthma and CF and occasionally COPD. Diagnosis requires positive Aspergillus fumigatus specific IgE antibody, serum IgE > 500iu/L and any 2 of (i) positive A. fumigatus IgG, (ii) eosinophil count > 500 cells/µL, (iii) HRCT thorax-bronchiectasis, mucus plugs or (iv) fleeting infiltrates on chest X-rays.12 Exacerbations are common which require oral corticosteroids or itraconazole for 3-4 months, or both if exacerbation refractory. Changing the azole is sometimes helpful. Omalizumab, anti-IL-5 and anti-IL-4/-13, in the presence of eosinophilia, can reduce exacerbations and steroid requirements. Nebulized Amphotericin helps maintain clinical remission.12 RA affects 1% of the general population. 3%-8% of RA patients have clinical bronchiectasis (RAB) and 20%-30% radiological bronchiectasis.13 Rheumatoid factor and anti-cycle citrullinated peptide antibodies are much more common in bronchiectasis patients than controls (18% vs. 2.8%). If both titres and very high, 50% develop RA within a year. In two-thirds bronchiectasis precedes RA raising the possibility of an inciting airway epitope. The mortality of RAB is 5 times that of RA alone probably due toxic combination of infection and immunosuppression. Ulcerative Colitis associated bronchiectasis is rare affecting 1%-2% of bronchiectasis cohorts. Patients can be highly productive which may respond very well to ICS alone, suggesting a pure inflammatory component.14 The common embryonic origins of the bowel and lungs and sharing common antigens is one hypothesis. Common variable immune (CVID) is the commonest cause of immunodeficiency in adults. All patients have IgG deficiency ± low IgA ± low IgM. Sinopulmonary infections are commonest followed by the gut. The low IgG also predisposes strongly to autoimmunity, granulomatous lymphocytic interstitial lung disease (GLILD) and malignancy in 10%15 X-linked agammaglobulinemia (XLA) is rare with an absence of circulating B cells. Diagnosis is usually achieved by the age of 3.75% and 28% of patients with XLA and CVID respectively have adult bronchiectasis. Occasionally patients have isolated low IgG antibodies to specific bacteria, e.g. Streptococcus pneumoniae or Haemophilus Influenzae. Treatment of these conditions is early institution of immunoglobulin replacement therapy (IgRT). 40%-60% of CLL patients have low IgG and 5% develop bronchiectasis. IgRT reduces the pneumonia and sepsis risk. A HRCT study showed a 10.7% prevalence in HIV patients who survived an opportunistic pneumonia. Primary cell dyskinesia (PCD) affects ciliary function and has a prevaIence of 1:7500, although the diagnosis is often missed or delayed. 50% of patients have Kartagener’s syndrome. Congenital heart disease occurs in 5% and neonates often present with a wet cough. A productive cough with rhinitis continues throughout childhood. Otitis media is extremely common by mid-teens. The upper lobes are often spared on HRCT suggesting that gravity alone can affect clearance. Nearly all adults develop bronchiectasis and Pseudomonas aeruginosa is common. Identification of a class 1 ultrastructural defect on electron microscopy or biallelic pathogenic variations in known causative genes confirms PCD.16 Genetic counselling, MTD care and fertility assessment follow diagnosis. mRNA therapies targeting specific mutations are in clinical trials. Tracheobronchomegaly (Mounier Kuhn syndrome) is a rare cause of bronchiectasis. The diagnosis is by HRCT (transverse tracheal diameter > 2.5 cm). It presents usually from age 20-50 with a marked male predominance. It has been associated with collagen disorders, connective tissue disease and prolonged ventilation in children. Trapped mucus leads to recurrent episodes of atelectasis and infection, with resultant distal bronchiectasis. Urgent bronchial toileting is often required. Benefit from Y-stenting and lung transplantation has been reported.17 GORD is thought to be a rare cause of bronchiectasis, and yet, it has a co-prevalence of 23%-75%. Aspiration of gastric contents exposes the airway to acid, pepsin, bile acids and gastric flora including anaerobes and NTM. A recent longitudinal case controlled, cohort study in a Korean population showed that in nearly 25 000 patients, symptomatic, proton pump inhibitor treated GORD had an increased prevalence of bronchiectasis (HR 1.43).18 The three main components are airway clearance, antibiotics and anti-inflammatory therapies. All productive patients should be taught airway clearance. This has little evidence base but reducing mucus accumulation decreases infection and atelectasis risk and possibly ameliorates progression of bronchiectasis. Only 50% of patients perform airway clearance.19 Active cycle of breathing is the most common method. Personalization of treatment improves compliance. Exercise, autogenic drainage, breath stacking, positive expiratory pressure and oscillating devices can all aid airway clearance.20 Pulmonary rehabilitation is efficacious and can be combined with airway clearance training. A recent study employing oral carbocysteine or inhaled hypertonic saline versus placebo showed a lack of benefit.21 An epithelial sodium channel blocker, in a phase 2 trial in PCD, showed benefit in FEV1 when the drug was given with hypertonic saline but not when given alone.22 Bronchodilators are appropriate in COPD and asthma. Proof of benefit in lung function, exercise or pre inhaled therapies in other aetiologies should be sought. Exacerbation recognition, collecting acute and convalescent sputum samples and a written action plan are critical for patients. An increase in ≥ 3 of increased sputum volume or purulence, fatigue, chest pain, dyspnoea, wheeze or haemoptysis > 48 h indicates an infection. Two weeks is the recommended antibiotic duration. Most dedicated units have a home intravenous antibiotic team. Hypoxia, type II respiratory failure, lobar atelectasis, pneumonia, marked secretions, severe haemoptysis, multi drug-resistant bacteria and poor social support necessitate admission. In western Europe H. influenzae predominates but in all of Europe P. aeruginosa is the commonest bacteria cultured.3 Other bacteria include Enterobacteriaceae, Staphylococcus aureus, S. pneumoniae and Moraxella catarrhalis in decreasing frequency. Inhaled antibiotics have the advantage of achieving high airway concentration with low systemic side effects. Inhaled gentamicin, tobramycin, colistin are all active against P. aeruginosa, and can delay the time to first exacerbation. They should be considered if patients are exacerbating ≥ twice a year. After first isolation of P. aeruginosa attempted eradication is recommended. Macrolides, particularly azithromycin, in a recent meta-analysis reduced exacerbations by 54% with the best efficacy in those colonized by P. aeruginosa.23 Only 17% of patients take macrolides due to fear of resistance developing including NTM. Side-effects include diarrhoea, hearing deficits and QT prolongation. Counselling about potential hearing loss and an ECG pre/post drug commencement is recommended. Brensocatib, blocks activation of the SP. In patients with ≥ 2 exacerbations per year, it increased the time to first exacerbation by 17%, slowed decline in FEV1 and improved QOL.2 BI 1291583, another DPP-1 inhibitor, in a phase 2 dose-finding study versus placebo revealed a significant dose-dependent benefit in time to first exacerbation over 48 weeks with a 30% exacerbation reduction with the 2 higher doses, 2.5 and 5 mg.24 CBO has the worst prognosis, with a 28% 5-year mortality, followed by RAB and PCD. P. aeruginosa is a biomarker of severe airway injury, as only then can this environmental bacillus survive there. It is becoming increasingly resistant both as a de novo infection and colonizer. It survives in protective biofilms and is associated with more exacerbations, a lower forced expiratory volume in 1 s (FEV1), lower BMI, worse bronchiectasis and higher mortality.25 There are 2 validated, commonly employed mortality prediction scores in bronchiectasis, the 9-variable Bronchiectasis Severity Index and the 5-variable FACED score.1 Bronchiectasis is a disease of many known aetiologies, and yet in over a third of cases the cause remains elusive. Dysregulated neutrophilic inflammation appears to be a critical factor in disease progression. Targeting the SP, given their proteolytic capacity and multiple downstream effects, has yielded new treatment options for this condition. Padraig Hawkins (Conceptualization [equal], Writing—original draft [equal], Writing—review & editing [equal]), Michael O’mahony (Writing—original draft [equal], Writing—review & editing [equal]), Michael John Harrison (Writing—original draft [equal], Writing—review & editing [equal]), Jack Robert Rutherford (Writing—original draft [supporting], Writing—review & editing [supporting]), Ruth Cusack (Writing—review & editing [supporting]), Melissa Jane Mcdonnell (Writing—review & editing [supporting]), Rachel O’neil (Writing—original draft [supporting], Writing—review & editing [supporting]), Niamh Duignan (Writing—original draft [supporting], Writing—review & editing [supporting]), John Bruzzi (Writing—original draft [supporting], Writing—review & editing [supporting]), and Chris Ward (Conceptualization [supporting], Writing—original draft [supporting], Writing—review & editing [supporting]), and Robert Michael Rutherford (Conceptualization [equal], Writing—original draft [lead], Writing—review & editing [equal]) None declared. None declared.
No takes yet. Share an insight, caveat, or question.
Hawkins et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: